Pfizer Inc. (PFE) Expected to Post Quarterly Sales of $12.90 Billion

Equities research analysts expect that Pfizer Inc. (NYSE:PFE) will post sales of $12.90 billion for the current quarter, Zacks reports. Two analysts have provided estimates for Pfizer’s earnings, with the highest sales estimate coming in at $12.97 billion and the lowest estimate coming in at $12.83 billion. Pfizer reported sales of $12.78 billion during the same quarter last year, which would suggest a positive year over year growth rate of 0.9%. The firm is expected to report its next quarterly earnings report on Tuesday, May 1st.

On average, analysts expect that Pfizer will report full year sales of $12.90 billion for the current year, with estimates ranging from $54.02 billion to $54.69 billion. For the next fiscal year, analysts expect that the company will report sales of $54.77 billion per share, with estimates ranging from $54.32 billion to $55.26 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Pfizer.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the prior year, the company earned $0.47 EPS. Pfizer’s revenue was up .6% compared to the same quarter last year.

A number of research analysts have recently commented on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research note on Thursday. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Societe Generale set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Leerink Swann increased their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $39.45.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Municipal Employees Retirement System of Michigan lifted its position in shares of Pfizer by 2.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 277,150 shares of the biopharmaceutical company’s stock worth $9,309,000 after buying an additional 6,870 shares in the last quarter. John G Ullman & Associates Inc. lifted its position in shares of Pfizer by 3.0% during the 2nd quarter. John G Ullman & Associates Inc. now owns 466,336 shares of the biopharmaceutical company’s stock worth $15,664,000 after buying an additional 13,494 shares in the last quarter. Longview Partners Guernsey LTD lifted its position in shares of Pfizer by 6.9% during the 2nd quarter. Longview Partners Guernsey LTD now owns 18,468,572 shares of the biopharmaceutical company’s stock worth $620,359,000 after buying an additional 1,189,059 shares in the last quarter. Eastern Bank lifted its position in shares of Pfizer by 1.4% during the 2nd quarter. Eastern Bank now owns 146,336 shares of the biopharmaceutical company’s stock worth $4,916,000 after buying an additional 1,969 shares in the last quarter. Finally, Boston Financial Mangement LLC lifted its position in shares of Pfizer by 6.8% during the 2nd quarter. Boston Financial Mangement LLC now owns 1,602,439 shares of the biopharmaceutical company’s stock worth $53,826,000 after buying an additional 102,128 shares in the last quarter. Institutional investors and hedge funds own 70.06% of the company’s stock.

Shares of Pfizer (NYSE PFE) traded up $0.55 on Tuesday, hitting $36.26. The stock had a trading volume of 26,240,000 shares, compared to its average volume of 27,730,000. Pfizer has a one year low of $31.67 and a one year high of $39.43. The company has a market cap of $216,140.00, a PE ratio of 10.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.94. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date of this dividend is Thursday, February 1st. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.

Pfizer announced that its Board of Directors has approved a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/18/pfizer-inc-pfe-expected-to-post-quarterly-sales-of-12-90-billion.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply